In Silico Clinical Trials Market, By Therapeutic Area (Oncology, Infectious Disease, Cardiology, Neurology, Diabetes, and Other Therapeutic Areas), By Industry (Medical Devices and Pharmaceutical), By Phase (Phase I, Phase II, Phase III, and Phase IV), And By Geography (North America, Europe, Asia-Pacific, South America, and Middle East and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
In silico clinical trials refers to the development of a patient-specific models to form virtual cohorts for testing the safety and efficacy of new drugs and of new medical devices. In silico clinical trials play an important role in the evaluation of new drugs and medical devices.
Market Dynamics:
Increase in prevalence of chronic, infectious, and neurological diseases, increasing use of in silico models to test medical devices, increase in number of in silico clinical trials, outbreak of COVID-19, and cost-effectiveness and less chances of termination of the trial are major factors expected to propel the growth of the global in silico clinical trials market.
For instance, in March 2022, 4P-Pharma signed a partnership with QuantHealth, a data science start-up taking a unique in-silico approach to clinical trial simulations based on broad real-world data (RWD) and deep molecular drug data. Together, 4P-Pharma and QuantHealth will conduct in silico clinical trials of their lead drug candidates. The partnership will start with in-silico simulation of the phase II clinical trial of 4P004, a first-in-class disease modifying osteoarthritis drug, which is developed by our spin-off, 4Moving Biotech.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook